Health
Moderna’s stock has surged 488% in 2020: Is it a buy for 2021? – Motley Fool Australia
This smaller biotech company attracted a lot of attention in 2020, but is it still worth an investment?
This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.
All eyes were on the biotech Moderna(NASDAQ: MRNA) in 2020. It wasn’t quite a popular name in the pharmaceutical space, as it has no approved products on the market yet. But its sudden entry in the COVID-19 vaccine competition grabbed a lot of attention, and it became the second company to win approval in a race with dozens of players. No wonder its stock has surged 488% so far this year,…
-
Business15 hours ago5 things to watch on the ASX 200 on Thursday 4 September 2025
-
Noosa News16 hours agoJazz festival wraps up | Noosa Today
-
Noosa News11 hours agoDog owners warned: $834 fine for pets not under control
-
Business17 hours agoA perfect 4.5% dividend stock paying cash every month in a volatile market